CHEPLAPHARM is delighted to announce an addition to its board of management.
With effect of April 1st, 2021 Dr. Keyarasch “Kia” Parssanedjad, M.D. joins the company´s management board as Chief Corporate Investment Officer (CIO).
Dr. Parssanedjad is an entrepreneurial healthcare leader, who has more than 15 years of hands-on experience in both building, managing as well as investing into innovative, high-growth healthcare and life science businesses.
Dr. Parssanedjad joins CHEPLAPHARM from McKinsey&Company, where he has been a co-leader of McKinsey’s global Leap practice in healthcare and life sciences focussing on business building with leading global clients. Previously, he held leadership roles at Merck Group. Dr. Parssanedjad is a trained physician and obtained his medical degree in the field of cancer research /gene therapy.
With this addition, CHEPLAPHARM further strengthens its management board by building on its core competence of corporate investments.